A $50 million pharmaceutical manufacturing campus is one step closer to opening along Allen's US-75 corrido.
BMK Pharma, founded by Frisco-based pharmaceutical entrepreneur Dr. Jay Bhaumik, plans to build a 50,000-square-foot sterile compounding and research facility near the intersection of Central Expressway and Exchange Parkway.
The Allen City Council is scheduled to consider the zoning change at its Tuesday, August 11, meeting.
The property is currently zoned for shopping center uses, which does not permit pharmaceutical manufacturing.
The requested change would reclassify it for drug and pharmaceutical manufacturing, allowing research, design, development, production, storage and sales of pharmaceutical products.
BMK Pharma also asked that electronic manufacturing and medical clinic uses be permitted on site.
Senior Planner Matt Bechtlufft told commissioners that staff recommended approval because the property doesn't function like a typical retail center.
"Staff is recommending approval of this item, and the reason for that is how the property itself developed throughout the years," Bechtlufft said. "Even though it has a base zoning of shopping center, if you look at the property, it doesn't look like your traditional shopping center."
The facility would serve as both a 503B compounding pharmacy and a sterile contract development and manufacturing organization, producing injectable drugs and sterile dosage forms for healthcare providers, according to an Allen Economic Development Corporation announcement from September 25, 2025.
A 503B compounding pharmacy is a federally regulated outsourcing facility that compounds drugs on a larger scale than a traditional pharmacy.
The project would create more than 100 jobs in Allen, including automation engineers, chemists, pharmacists and scientific researchers, according to the Allen EDC's September 2025 announcement.
Dallas Innovates reported in October 2025 that the company planned to invest $50 million in the facility.
BMK Pharma previously requested a similar zoning change for a property directly to the south of the current site. In that earlier request, the company proposed a Level 2 biosafety laboratory but reduced it to Level 1 after city officials raised safety concerns, Bechtlufft said.
The current request also includes a Level 1 biosafety lab. The outcome of that earlier request could not be confirmed from available public records.
The Allen EDC initially projected a third-quarter 2026 opening, but the zoning process remains underway. No updated timeline has been announced.
Meeting agendas and details for the August 11 council session are available at the city's website.
